Market Cap

PolyPeptide Group AG Market Capitalization:

CHF1.03 Billion

CHF as of July 1, 2024

US$1.14 Billion

business PolyPeptide Group AG Company Profile

PolyPeptide Group AG Main Stock Listing

SIX: PPGN

Market Capitalization History of PolyPeptide Group AG

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Top Competitors by Market Capitalization

Industry: Drug Manufacturers—Specialty & Generic
Company Market Cap (USD)
Zoetis Inc. $80.13 B
MERCK Kommanditgesellschaft auf Aktien $71.24 B
Takeda Pharmaceutical Company Limited $41.23 B
Haleon plc $37.32 B
Teva Pharmaceutical Industries Limited $18.88 B
Sector: Healthcare
Company Market Cap (USD)
Lilly $808.65 B
Novo Nordisk $622.07 B
UnitedHealth Group $450.89 B
Johnson & Johnson $350.63 B
Merck $318.75 B

Yearly evolution of PolyPeptide Group AG market cap

Date Market Cap YoY Change
Jan. 1, 2024 CHF559.1 M -38.50%
Jan. 1, 2023 CHF909.0 M -70.24%
Jan. 1, 2022 CHF3.05 B

Market capitalization is calculated from the opening stock price at the beginning of each year.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

PolyPeptide Group AG Categories

Switzerland languages Healthcare languages Drug Manufacturers—Specialty & Generic
Switzerland Healthcare Switzerland Drug Manufacturers—Specialty & Generic

Stocks & Indices

PolyPeptide Group AG has the following listings and related stock indices.


Stock: SIX: PPGN

What is a company's market capitalization?

The market capitalization of a company, more simply referred to as "market cap", is the total market value of a publicly traded company's outstanding shares. It is often considered as a key indicator of what a company is worth.